Prominent publications by Johannes Jacob Pieter Kastelein

KOL Index score: 21141

BACKGROUND: Statin therapy has been shown to reduce major vascular events and vascular mortality in a wide range of individuals, but there is uncertainty about its efficacy and safety among older people. We undertook a meta-analysis of data from all large statin trials to compare the effects of statin therapy at different ages.

METHODS: In this meta-analysis, randomised trials of statin therapy were eligible if they aimed to recruit at least 1000 participants with a scheduled treatment ...

Known for Statin Therapy |  Older People |  Major Vascular Events |  75 Years |  Age Patients
KOL Index score: 20624

Importance: Some cholesteryl ester transfer protein (CETP) inhibitors lower low-density lipoprotein cholesterol (LDL-C) levels without reducing cardiovascular events, suggesting that the clinical benefit of lowering LDL-C may depend on how LDL-C is lowered.

Objective: To estimate the association between changes in levels of LDL-C (and other lipoproteins) and the risk of cardiovascular events related to variants in the CETP gene, both alone and in combination with variants in the ...

Known for Cardiovascular Risk |  Cetp Inhibitors |  Genetic Variants |  Lipoprotein Levels |  Hdl Cholesterol
KOL Index score: 20215

CONTEXT: Interest remains high in cholesteryl ester transfer protein (CETP) inhibitors as cardioprotective agents. Few studies have documented the efficacy and safety of CETP inhibitors in combination with commonly used statins.

OBJECTIVE: To examine the biochemical effects, safety, and tolerability of evacetrapib, as monotherapy and in combination with statins, in patients with dyslipidemia.

DESIGN, SETTING, AND PARTICIPANTS: Randomized controlled trial conducted among 398 patients with ...

Known for Evacetrapib Monotherapy Combination |  Hdl Cholesterol |  Statin Monotherapy |  Randomized Controlled |  12 Weeks
KOL Index score: 19754

Importance: Reducing levels of low-density lipoprotein cholesterol (LDL-C) with intensive statin therapy reduces progression of coronary atherosclerosis in proportion to achieved LDL-C levels. Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors produce incremental LDL-C lowering in statin-treated patients; however, the effects of these drugs on coronary atherosclerosis have not been evaluated.

Objective: To determine the effects of PCSK9 inhibition with evolocumab on ...

Known for Coronary Disease |  Randomized Clinical Trial |  Patients Placebo |  Humanized Cholesterol |  Difference 95
KOL Index score: 19197

OBJECTIVES: The severe forms of hypertriglyceridaemia (HTG) are caused by mutations in genes that lead to the loss of function of lipoprotein lipase (LPL). In most patients with severe HTG (TG > 10 mmol L(-1) ), it is a challenge to define the underlying cause. We investigated the molecular basis of severe HTG in patients referred to the Lipid Clinic at the Academic Medical Center Amsterdam.

METHODS: The coding regions of LPL, APOC2, APOA5 and two novel genes, lipase maturation factor 1 ...

Known for Mutations Lpl |  Apoc2 Apoa5 |  Severe Htg |  Molecular Basis |  Lipoprotein Lipase
KOL Index score: 18455

Importance: Triglycerides and cholesterol are both carried in plasma by apolipoprotein B (ApoB)-containing lipoprotein particles. It is unknown whether lowering plasma triglyceride levels reduces the risk of cardiovascular events to the same extent as lowering low-density lipoprotein cholesterol (LDL-C) levels.

Objective: To compare the association of triglyceride-lowering variants in the lipoprotein lipase (LPL) gene and LDL-C-lowering variants in the LDL receptor gene (LDLR) with the ...

Known for Coronary Heart Disease |  Risk Chd |  Lowering Lpl |  Triglyceride Levels |  Cardiovascular Events
KOL Index score: 17840

Mutations in ABCA1, APOA1, and LCAT reduce HDL cholesterol (HDLc) in humans. However, the prevalence of these mutations and their relative effects on HDLc reduction and risk of coronary artery disease (CAD) are less clear. Here we searched for ABCA1, APOA1, and LCAT mutations in 178 unrelated probands with HDLc <10th percentile but no other major lipid abnormalities, including 89 with ≥1 first-degree relative with low HDLc (familial probands) and 89 where familial status of low HDLc is ...

Known for Coronary Artery Disease |  Mutations Abca1 |  Hdl Cholesterol Hdlc |  Lcat Cad |  Binding Cassette
KOL Index score: 17720

BACKGROUND: Inflammation in the tumour microenvironment mediated by interleukin 1β is hypothesised to have a major role in cancer invasiveness, progression, and metastases. We did an additional analysis in the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS), a randomised trial of the role of interleukin-1β inhibition in atherosclerosis, with the aim of establishing whether inhibition of a major product of the Nod-like receptor protein 3 (NLRP3) inflammasome with ...

Known for Placebo Canakinumab |  Lung Cancer |  Monoclonal Antibodies |  Controlled Trial |  Patients Atherosclerosis
KOL Index score: 17203

CONTEXT: Evidence suggests that more intensive lowering of low-density lipoprotein cholesterol (LDL-C) than is commonly applied clinically will provide further benefit in stable coronary artery disease.

OBJECTIVE: To compare the effects of 2 strategies of lipid lowering on the risk of cardiovascular disease among patients with a previous myocardial infarction (MI).

DESIGN, SETTING, AND PARTICIPANTS: The IDEAL study, a prospective, randomized, open-label, blinded end-point evaluation ...

Known for Ideal Study |  Dose Atorvastatin |  Myocardial Infarction |  95 Patients |  2 Groups
KOL Index score: 16891

OBJECTIVES: The goal of this study was to determine whether residual risk after high-dose statin therapy for primary prevention individuals with reduced levels of low-density lipoprotein cholesterol (LDL-C) is related to on-treatment apolipoprotein B, non-high-density lipoprotein cholesterol (non-HDL-C), trigylcerides, or lipid ratios, and how they compare with on-treatment LDL-C.

BACKGROUND: Guidelines focus on LDL-C as the primary target of therapy, yet residual risk for cardiovascular ...

Known for Residual Risk |  Hdl Cholesterol |  Density Lipoprotein |  Statin Therapy |  Treatment Ldl
KOL Index score: 16529

BACKGROUND: Canakinumab, a monoclonal antibody targeting interleukin-1β, reduces inflammation and cardiovascular event rates with no effect on lipid concentrations. However, it is uncertain which patient groups benefit the most from treatment and whether reductions in the inflammatory biomarker high-sensitivity C-reactive protein (hsCRP) correlate with clinical benefits for individual patients.

METHODS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) used ...

Known for Controlled Trial |  Treatment Canakinumab |  Secondary Analysis |  Reactive Protein |  Monoclonal Antibodies
KOL Index score: 16420

Importance: It remains uncertain whether the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) reduce cardiovascular risk.

Objective: To determine the effects on cardiovascular outcomes of a carboxylic acid formulation of EPA and DHA (omega-3 CA) with documented favorable effects on lipid and inflammatory markers in patients with atherogenic dyslipidemia and high cardiovascular risk.

Design, Setting, and Participants: A double-blind, randomized, multicenter ...

Known for Cardiovascular Risk |  Corn Oil |  Fatty Acid |  Major Adverse |  Epa Dha
KOL Index score: 16404

CONTEXT: The associations of low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and apolipoprotein B (apoB) levels with the risk of cardiovascular events among patients treated with statin therapy have not been reliably documented.

OBJECTIVE: To evaluate the relative strength of the associations of LDL-C, non-HDL-C, and apoB with cardiovascular risk among patients treated with statin therapy.

DESIGN: Meta-analysis of individual patient data ...

Known for Cardiovascular Events |  Hdl Cholesterol |  Statin Therapy |  Apob Ldl
KOL Index score: 16403

AMR101 is an omega-3 fatty acid agent containing ≥96% eicosapentaenoic acid ethyl ester and no docosahexaenoic acid. Previous smaller studies suggested that highly purified eicosapentaenoic acid lowered triglyceride (TG) levels without increasing low-density lipoprotein (LDL) cholesterol levels. TG-lowering therapies such as fibrates, and fish oils containing both eicosapentaenoic acid and docosahexaenoic acid, can substantially increase LDL cholesterol levels when administered to ...

Known for Tg Levels |  Day Placebo |  Eicosapentaenoic Acid |  Ethyl Ester |  Week Study
KOL Index score: 15900

BACKGROUND: Increased levels of the inflammatory biomarker high-sensitivity C-reactive protein predict cardiovascular events. Since statins lower levels of high-sensitivity C-reactive protein as well as cholesterol, we hypothesized that people with elevated high-sensitivity C-reactive protein levels but without hyperlipidemia might benefit from statin treatment.

METHODS: We randomly assigned 17,802 apparently healthy men and women with low-density lipoprotein (LDL) cholesterol levels of ...

Known for Reactive Protein |  Hazard Ratio 95 |  Prevent Vascular Events |  Stroke Death |  Myocardial Infarction


Johannes Jacob Pieter Kastelein: Influence Statistics

Sample of concepts for which Johannes Jacob Pieter Kastelein is among the top experts in the world.
Concept World rank
dalcetrapib treatment fch #1
withinreader #1
carat cer001 #1
hypercholesterolemia fh #1
ta‐8995 #1
ldlc ldlr #1
abca1 cad #1
landmark statin trials #1
rlpc levels fh #1
hmgcr inhibitors statins #1
bococizumab placebo #1
corneal opacity fed #1
mutation m‐21v #1
ihtg content week #1
cetp inhibitors combination #1
or25mmol #1
lpl ser447stop mutation #1
mace north america #1
treatment eprotirome #1
g824a #1
lipoprotein lipase mutation #1
statin therapy mipomersen #1
efficacy pitavastatin #1
22rohchol #1
human lpls447x #1
mutation 18 patients #1
acs carat #1
cardiovascular events late #1
inclisiran subcutaneous injection #1
vitro lpl activity #1
cetp galnt2 mutations #1
statin therapy effects #1
patients atv10 #1
carriers d9n #1
underlying genetic mutations #1
lipg cetp #1
individuals adh phenotype #1
predictive apoa1 #1
clinical manifestations cvd #1
multilocus haplotype effects #1
ldl treatment #1
10 ta8995 #1
mimetic particle cer001 #1
w24 placebo #1
early repair patients #1
patients combined trials #1
hefhmethods #1
hefh boys girls #1
atv80 atv10 #1
patients fh #1

Key People For Familial Hypercholesterolemia

Top KOLs in the world
Johannes Jacob Pieter Kastelein
familial hypercholesterolemia hdl cholesterol lipoprotein lipase
Stephen Eric Humphries
familial hypercholesterolaemia coronary heart disease genetic variation
Joep C Defesche
familial hypercholesterolemia cardiovascular disease fh patients
Gerald Francis FRANCIS WATTS
familial hypercholesterolaemia metabolic syndrome statin therapy
Robert Alexander Hegele
metabolic syndrome type 2 diabetes blood pressure
Eric J G Sijbrands
type 2 diabetes familial hypercholesterolemia cardiovascular disease

Johannes Jacob Pieter Kastelein:Expert Impact

Concepts for whichJohannes Jacob Pieter Kasteleinhas direct influence:Familial hypercholesterolemia,  Hdl cholesterol,  Cardiovascular disease,  Lipoprotein lipase,  Statin therapy,  Familial hypercholesterolaemia,  Cardiovascular risk,  Cardiovascular events.

Johannes Jacob Pieter Kastelein:KOL impact

Concepts related to the work of other authors for whichfor which Johannes Jacob Pieter Kastelein has influence:Cardiovascular disease,  Metabolic syndrome,  Familial hypercholesterolemia,  Statin therapy,  Hdl cholesterol,  Myocardial infarction,  Type 2 diabetes.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: | Department of Vascular Medicine, Academic Medical Centre, Amsterdam, the Netherlands. | Academic

FREE Custom List